ENTA—Today's announcement of the clinical advancement of EDP-239 (#msg-105063800) is probably the reason ENTA's CSO exercised options two days ago without selling the new shares. This is perfectly legal, of course.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”